Ipsen shares slide 7% as FDA approves generic Somatuline
Shares in Ipsen fell about 7% after the US Food and Drug Administration approved Amneal's generic version of the company's blockbuster drug Somatuline. Both J.P. Morgan and Jefferies see the FDA approval as increasing pressure on Somatuline, with JPM noting it could cause low single-digit downward revisions to FY26 con